Identifying breast cancer patients most likely to benefit from trastuzumab

[News]

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

More... (http://www.medicalnewstoday.com/releases/270018.php)